×
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)

Pro-Dex Stock Forecast, Price & News

$15.95
0.00 (0.00%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.10
$16.43
50-Day Range
$13.16
$16.51
52-Week Range
$12.40
$32.00
Volume
10,777 shs
Average Volume
9,195 shs
Market Capitalization
$57.72 million
P/E Ratio
18.33
Dividend Yield
N/A
Price Target
$30.00
30 days | 90 days | 365 days | Advanced Chart

Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock Forecast (MarketRank)

Overall MarketRank

1.70 out of 5 stars

Medical Sector

909th out of 1,433 stocks

Surgical & Medical Instruments Industry

98th out of 139 stocks

Analyst Opinion: 2.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
Pro-Dex logo

About Pro-Dex (NASDAQ:PDEX)

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.

PDEX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDEX
Employees
117
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/30/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
8/25/2022

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+88.1%
Consensus Rating
N/A
Rating Score (0-4)
3
Research Coverage
0 Analysts

Profitability

Net Income
$4.45 million
Pretax Margin
7.20%

Debt

Sales & Book Value

Annual Sales
$38.03 million
Cash Flow
$1.46 per share
Book Value
$5.50 per share

Miscellaneous

Free Float
2,128,000
Market Cap
$57.72 million
Optionable
Not Optionable
Beta
1.11














Pro-Dex Frequently Asked Questions

What is Pro-Dex's stock price forecast for 2022?

0 Wall Street analysts have issued 1-year target prices for Pro-Dex's shares. Their PDEX stock forecasts range from $30.00 to $30.00. On average, they anticipate Pro-Dex's stock price to reach $30.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price.
View analysts' price targets for Pro-Dex
or view top-rated stocks among Wall Street analysts.

How has Pro-Dex's stock price performed in 2022?

Pro-Dex's stock was trading at $23.21 at the beginning of the year. Since then, PDEX shares have decreased by 34.1% and is now trading at $15.30.
View the best growth stocks for 2022 here
.

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022.
View our earnings forecast for Pro-Dex
.

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) released its quarterly earnings data on Thursday, May, 5th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $9.27 million for the quarter. Pro-Dex had a trailing twelve-month return on equity of 15.41% and a net margin of 8.50%.
View Pro-Dex's earnings history
.

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the following people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 61, Pay $416.15k)
  • Ms. Alisha K. Charlton, CFO & Corp. Sec. (Age 52, Pay $242.53k) (LinkedIn Profile)
  • Ms. Angel Rebamontan Domingo, Director and Director of Regulatory Affairs & Quality Assurance

What is Michael J. Berthelot's approval rating as Pro-Dex's CEO?

3 employees have rated Pro-Dex CEO Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among Pro-Dex's employees.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH).

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $15.30.

How much money does Pro-Dex make?

Pro-Dex (NASDAQ:PDEX) has a market capitalization of $55.37 million and generates $38.03 million in revenue each year. The medical instruments supplier earns $4.45 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Pro-Dex have?

Pro-Dex employs 117 workers across the globe.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for Pro-Dex is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at [email protected], or via fax at 949-769-3281.

This page (NASDAQ:PDEX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.